Thermo Fisher Scientific Inc. $TMO Shares Purchased by Veritas Asset Management LLP

Veritas Asset Management LLP lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 882,873 shares of the medical research company’s stock after acquiring an additional 36,878 shares during the period. Thermo Fisher Scientific accounts for approximately 8.2% of Veritas Asset Management LLP’s portfolio, making the stock its 6th biggest holding. Veritas Asset Management LLP’s holdings in Thermo Fisher Scientific were worth $442,637,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Bank OZK purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $456,000. North Dakota State Investment Board acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at $7,505,000. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $15,501,867,000. Finally, German American Bancorp Inc. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $4,920,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.7%

NYSE:TMO traded down $10.35 during trading hours on Tuesday, hitting $603.43. 2,695,109 shares of the company’s stock traded hands, compared to its average volume of 2,241,478. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The firm has a market cap of $223.12 billion, a P/E ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock’s fifty day moving average price is $575.12 and its two-hundred day moving average price is $516.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the business posted $4.28 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analysts Set New Price Targets

TMO has been the subject of several analyst reports. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. UBS Group raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 28th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.